Company / R&D per Share
VYNE Therapeutics Inc. R&D per Share History
FY2018-FY2025 · Annual data · Source: SEC filings
At a glance
Latest annual filing availableLatest R&D per Share
$2.09
FY2025
5-year range
$1.01 / $6.57
FY2021-FY2025
Trend
+80.4%
vs FY2024
Sector context
Sector data unavailable
Latest sector comparison
What the data says
R&D per Share returned to growth in FY2025 after 2 years of decline, reaching $2.09.
Based on SEC 10-K filings.
2.09 in FY2025 with a 5-year CAGR of -21.7%.
Declined from $5.69 to $2.09 over the past 2 years.
R&D per Share over time
Growth rates
- 3-Year CAGR
- -31.8%
- 5-Year CAGR
- -21.7%
- 10-Year CAGR
- -
Key checks
Key Insights
- In FY2025, r&d per share increased 80.4% year-over-year.
- Peak r&d per share was recorded in FY2020.
- Lowest r&d per share in the period was in FY2021.
Company context
Key Data Points
- Low Piotroski F-Score: 2/9 (multiple financial health concerns)
- Altman Z-Score -3.19 (distress zone, below 1.8 threshold)
- High earnings quality (cash-backed earnings)
Data sourced from SEC EDGAR filings. Not investment advice.
Annual data
| Year | R&D per ShareValue | YoY GrowthYoY |
|---|---|---|
| FY2025 | $2.09 | +80.4% |
| FY2024 | $1.16 | -79.7% |
| FY2023 | $5.69 | -13.3% |
| FY2022 | $6.57 | +551.6% |
| FY2021 | $1.01 | -85.7% |
| FY2020 | $7.07 | +466.2% |
| FY2019 | $1.25 | -41.2% |
| FY2018 | $2.12 | - |
As of FY2025 · SEC 10-K · Updated Jun 28, 2026